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Editorial Comment
“Triple Therapy” or Triple Threat?
Balancing the Risks of Antithrombotic Therapy for Patients
With Atrial Fibrillation and Coronary Stents*
Steven Francescone, MD, Jonathan L. Halperin, MD, FACC
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ratients with atrial fibrillation (AF) who have additional
isk factors for thromboembolism benefit from chronic
nticoagulant therapy (1). When these patients undergo
ercutaneous coronary intervention (PCI), the need for
latelet inhibitor medication poses a particular clinical
hallenge because the risk of bleeding is significantly in-
reased, especially when “triple therapy” with a combination
f warfarin, aspirin, and a thienopyridine is used. Scant data
re available to guide management of such patients.
See page 818
First, consider the imperative of preventing ischemic
troke in patients with AF. Warfarin reduces thromboem-
olism by about one-half while increasing major bleeding to
% to 2% per year and doubling the risk of intracranial
emorrhage (2). For the highest-risk AF patients (those
ith prior stroke, transient ischemic attack, or mechanical
eart valves), the benefit of anticoagulation generally out-
eighs the bleeding risk. On the other hand, low-risk
atients can be adequately treated with aspirin alone (1).
nalysis of data from 12 randomized trials directly compar-
ng the treatments in 12,721 patients, predominantly for
rimary prevention, favors anticoagulation with a vitamin K
ntagonist over antiplatelet therapy (relative risk reduction
RR] about 40%, absolute RR about 1% per year) (2).
nticoagulation was also superior to the combination of
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nvolving gene therapy for patients with severe peripheral arterial disease.spirin plus clopidogrel in a large trial (6,706 patients; RR
eduction 40% [95% confidence interval 18% to 56%]) (3).
The problem stems from differences in the predominant
athophysiological processes involved in myocardial infarc-
ion (MI) and ischemic stroke: atherothrombosis versus
ardiogenic embolism and the choice of antithrombotic
herapy that results. In patients with coronary artery disease,
latelet inhibitor therapy is generally prescribed. Although
spirin is the prophylactic antiplatelet drug of choice, it
educes the risk of recurrent stroke, MI, and vascular death
y only 13% (4). Clopidogrel was 8% better than aspirin in
ne large trial and associated with fewer gastrointestinal
leeding complications (5).
After PCI, dual antiplatelet therapy with aspirin plus a
hienopyridine is superior to aspirin alone (6,7), warfarin alone,
r warfarin plus aspirin (6,8,9). Addition of clopidogrel to
spirin in patients with acute coronary syndromes undergoing
CI significantly reduced rates of myocardial infarction and
ardiovascular death (6.0% vs. 8.0%) at an average follow-up of
months (7). The trial was underpowered, however, to assess
he efficacy of dual antiplatelet therapy compared with aspirin
lone for stroke prevention (10). This and other trials support
dministering the combination of clopidogrel plus aspirin for 4
eeks after elective PCI and for up to 8 months in the acute
etting when bare-metal stents (BMS) are used.
The cumulative incidence of target lesion revascularization is
ower with drug-eluting stents (DES) (1.9%/year) than with
MS (5%/year), with the majority of events occurring in the
rst year with either type of device (11). An apparently greater
ncidence of late stent thrombosis in patients treated with
ES, is attributed to delayed re-endothelialization and higher
omplexity of coronary lesions (12,13). Stent thrombosis with
ES can occur beyond the first year and has been associated
ith interruption of clopidogrel (14).
The inherent risk of prolonged antiplatelet therapy is
leeding (10), which is compounded by adding an antico-
gulant. In a secondary analysis of a randomized trial
atabase, addition of aspirin (up to 100 mg daily) in patients
ith AF who were on warfarin (international normalized
atio 2.0 to 3.0) increased major bleeding (3.9%/year)
ompared with warfarin alone (2.3%/year, p  0.01) with-
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February 26, 2008:826–7 Editorial Commentut reducing stroke and systemic embolism or MI (15).
Triple therapy” has been associated with major bleeding
ates as high as 7%/year (16).
In the series of patients with AF undergoing PCI
escribed by Ruiz-Nodar et al. (17), omission of anticoag-
lation at discharge was associated with increased mortality
nd major adverse cardiovascular events at a median
ollow-up interval of 595 days, the longest observation
eriod yet reported. The reduction in adverse events with
egimens that included an anticoagulant was mainly attrib-
table to lower rates of mortality and ischemic stroke.
atients with renal failure or acute ST-segment elevation
I were more likely to receive dual antiplatelet therapy
ithout anticoagulation, and this may have contributed to
he difference in mortality. There was no significant differ-
nce in rates of stent thrombosis between the groups.
The data were derived from retrospective analysis and
ntailed the considerable variability in the type and duration of
ntithrombotic therapy that typically characterizes practice in
he absence of clear and consistent evidence-based guidelines.
hese limitations preclude reasonable recommendations re-
arding the safety and efficacy of triple therapy. Even so, the
tudy highlights the importance of maintaining anticoagula-
ion in patients with AF undergoing PCI. In the absence of
andomized trials, physicians must individualize antithrom-
otic therapy, taking into account the risks of hemorrhage,
hromboembolism, and stent thrombosis. Patients with AF
ho have more than 1 moderate risk factor for thromboem-
olism (clinical heart failure or impaired left ventricular systolic
unction [ejection fraction less than or equal to 35%], history of
ypertension, age 75 years, diabetes mellitus, prior stroke or
ransient ischemic attack score  2 or more) (18) should
esume anticoagulation as soon as feasible after PCI. For those
t low risk of serious bleeding, treatment with triple therapy
ay be the best option. Perhaps more to the point, BMS may
e preferable to DES in patients with AF who have risk factors
or thromboembolism requiring chronic anticoagulation to
educe the need for prolonged combination therapy.
A pressing question is whether beyond the first few weeks
fter stent deployment a maintenance regimen consisting of
arfarin plus clopidogrel alone would preserve efficacy while
educing the risk of gastrointestinal bleeding (19). The answer
ill require additional studies not only in patients with AF but
lso in the broader population of patients with coronary artery
isease who have an ongoing need for anticoagulation.
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